Thrombocytopenia associated with second-line carboplatin-based chemotherapy for ovarian, fallopian tube, and primary peritoneal cavity cancers

被引：0
|
作者：
Maurie Markman
Jon Markman
Kenneth Webster
Kristine Zanotti
Barbara Kulp
Gertrude Peterson
Jerome Belinson
机构：
[1] University of Texas M.D. Anderson Cancer Center ,Departments of Hematology/Medical Oncology and Gynecology/Obstetrics
[2] The Cleveland Clinic Foundation,undefined
来源：
Journal of Cancer Research and Clinical Oncology | 2004年 / 130卷
关键词：
Thrombocytopenia; Carboplatin; Ovarian cancer; Chemotherapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：741 / 744
页数：3
相关论文
共 50 条
  • [41] Phase 2 trial of interferon-beta as second-line treatment of ovarian cancer, fallopian tube cancer, or primary carcinoma of the peritoneum
    Markman, M
    Belinson, J
    Webster, K
    Zanotti, K
    Morrison, B
    Jacobs, B
    Borden, E
    Lindner, D
    ONCOLOGY, 2004, 66 (05) : 343 - 346
  • [42] What Is the Benefit of Bevacizumab Combined with Chemotherapy in Patients with Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Malignancies?
    Cheng, X.
    Moroney, J. W.
    Levenback, C. F.
    Fu, S.
    Jaishuen, A.
    Kavanagh, J. J.
    JOURNAL OF CHEMOTHERAPY, 2009, 21 (05) : 566 - 572
  • [43] The contribution of deleterious germ-line mutations of susceptibility genes to ovarian, fallopian tube, and peritoneal cancers in Japanese
    Hirasawa, Akira
    Imoto, Issei
    Naruto, Takuya
    Akahane, Tomoko
    Yamagami, Wataru
    Susumu, Nobuyuki
    Tsuda, Hitoshi
    Aoki, Daisuke
    CANCER RESEARCH, 2017, 77
  • [44] Prognostic impact of the pretherapeutic hemoglobin level for patients with primary ovarian cancer receiving a carboplatin-based chemotherapy
    Eichbaum, M. H. R.
    Weiss, L.
    Bruckner, T.
    Gebauer, G.
    Schneeweiss, A.
    Fersis, N.
    Sohn, C.
    EJC SUPPLEMENTS, 2005, 3 (02): : 269 - 270
  • [45] The contribution of pathogenic variants of cancer susceptibility genes for primary ovarian, fallopian tube, and peritoneal cancers in Japanese.
    Hirasawa, Akira
    Imoto, Issei
    Takuya, Naruto
    Akahane, Tomoko
    Yamagami, Wataru
    Nomura, Hiroyuki
    Masuda, Kiyoshi
    Susumu, Nobuyuki
    Tsuda, Hitoshi
    Aoki, Daisuke
    CLINICAL CANCER RESEARCH, 2018, 24 (15) : 40 - 40
  • [46] Efficacy and safety of dose-dense paclitaxel plus carboplatin as neoadjuvant chemotherapy for advanced ovarian, fallopian tube or peritoneal cancer
    Yoshihama, Tomoko
    Nomura, Hiroyuki
    Iwasa, Naomi
    Kataoka, Fumio
    Hashimoto, Shiho
    Nanki, Yoshiko
    Hirano, Takuro
    Makabe, Takeshi
    Sakai, Kensuke
    Yamagami, Wataru
    Hirasawa, Akira
    Aoki, Daisuke
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2017, 47 (11) : 1019 - 1023
  • [47] Toxicity and survival associated with IV/IP chemotherapy following neoadjuvant chemotherapy and interval debulking surgery for epithelial ovarian, fallopian tube, and primary peritoneal cancer
    Rios-Doria, E.
    Pezzillo, M.
    Ulm, M. A.
    Tillmanns, T.
    GYNECOLOGIC ONCOLOGY, 2020, 159 : 127 - 128
  • [48] Tolerance of twenty-four hour paclitaxel and carboplatin as first-line therapy in ovarian, peritoneal and fallopian tube carcinoma
    Rose, PG
    Fusco, N
    Fluellen, L
    Rodriguez, M
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 1999, 9 (06) : 448 - 451
  • [49] Chemotherapy completion in the older adults with epithelial ovarian, fallopian tube, and primary peritoneal cancer at a university hospital in Thailand
    Assavapokee, Nicha
    Phoolcharoen, Natacha
    Santibenchakul, Somsook
    Lertkhachonsuk, Ruangsak
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 (SUPPL_4) : A69 - A70
  • [50] Pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancers: Results of a phase II study.
    del Carmen, M. G.
    Micha, J. P.
    Small, L. A.
    Street, D. G.
    Londhe, A.
    McGowan, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345